BBR Partners’s Altimmune ALT Stock Holding History

BBR Partners’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-374,784	Closed	-$2.49M	–	243
2024 Q2	$2.49M	Buy	374,784 +16,271	+5%	+$120K	0.2%	48
2024 Q1	$3.65M	Buy	+358,513	New	+$3.65M	0.29%	40

Other funds holding ALT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BBR Partners's ALT Position: Q3 2024 in Review

BBR Partners sold out of Altimmune (ALT) in Q3 2024, closing a stake of 374,784 shares — an estimated $2.49M sold.

BBR Partners first reported a position in ALT in Q1 2024 and held it in 2 quarters. The position peaked at $3.65M in Q1 2024. 169 funds tracked by Wall St. Rank hold ALT as of Q3 2024.

BBR Partners reported no remaining Altimmune position as of Q3 2024 after selling out during the quarter.
BBR Partners sold 374,784 Altimmune shares in Q3 2024, an estimated $2.49M.
BBR Partners first reported a position in Altimmune in Q1 2024 and held it in 2 quarters.
BBR Partners's Altimmune position peaked at $3.65M in Q1 2024.
169 funds tracked by Wall St. Rank held Altimmune as of Q3 2024.

Based on BBR Partners's 13F filing for Q3 2024, filed 13 Nov 2024.